Skip to content
DataLookout
Start free
Menu

NCT07377682

Real-world Clinical Response to Trazodone in Italy, Poland, and Romania

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved at least 4 months later.

See at-risk trials from Aziende Chimiche Riunite Angelini Francesco S.p.A

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 13 words
    • Primary and study completion pushed from Jul 2026 to Dec 2026
    • Secondary endpoints: details revised at 8 of 8 entries
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Depressive symptoms severity (MADRS)
Timeframe: At 24 weeks from treatment

Secondary (8)

Depressive symptoms severity (MADRS)
Clinical response (CGI)
Cognitive functioning (MoCA)
Sleep quality (SQS)
To describe the response in terms of quality of life (EQ-5D-5L)
Show 3 moreShow less
Absolute and relative frequency of patients
Serious adverse events of prolonged release trazodone
Drug related adverse events of prolonged release trazodone

Sites

1 site in 1 country

  • Poradnia Medycyna Miłorząb: pl. Pokoju 3/4, 90-227 Łódź. PolandLodz, Poland, Poland